VZNKUL-NMIBC Program Shows Promise in Bladder Cancer Treatment
• The VZNKUL-NMIBC program, a Flemish prospective cohort, monitors treatment quality for non-muscle-invasive bladder cancer (NMIBC) since 2013.
• Analysis of 2237 patients revealed that 60.4% had NMIBC, with variations in treatment adherence to European Association of Urology (EAU) guidelines.
• The study reported five-year recurrence-free, progression-free, and overall survival rates of 53%, 91.6%, and 70.6% for NMIBC patients, respectively.
• The registry's real-world data supports research, international collaboration, and enables hospitals to benchmark performance and improve patient care.
© Copyright 2025. All Rights Reserved by MedPath